-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of the PBS-subsidised eculizumab for
patients with atypical haemolytic uraemic syndrome (aHUS).

aHUS and listing dates

aHUS is a rare and life-threatening immune condition that causes
abnormal blood clots to form in small blood vessels in the kidneys.

Listing date:

-   eculizumab - 1 December 2014

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page links to application forms, contact details, dosing
schedule and treatment chart, item and restriction codes, the PBS
schedule and the Services Australia website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
